Biological therapies in inflammatory bowel disease: Top-down or bottom-up?

Current Opinion in Gastroenterology

Volumn 23, Issue 4, 2007, Pages 395-399

  Oldenburg, Bas ^a   Hommes, Daan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti tumour necrosis factor drugs; Inflammatory bowel disease; Top down therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; FONTOLIZUMAB; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VISILIZUMAB;

BIOLOGICAL THERAPY; CANCER RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED CANCER; DRUG TARGETING; ENTERITIS; ENVIRONMENTAL FACTOR; HEREDITY; HIGH RISK PATIENT; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INTESTINE MUCOSA; LYMPHOMA; MONOTHERAPY; PNEUMOCYSTIS PNEUMONIA; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; ULCERATIVE COLITIS; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34249929951     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32815b601b     Document Type: Review

References (57)

1. Travis SPL, Stange EF, Lémann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006; 55:i16-i35. Well balanced review and practical guidelines for treatment of Crohn's disease.
2. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (Suppl 5):1-16.
3. Hommes DW, Oldenburg B, van Bodegraven AA, et al. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med 2006; 64:219-229.
4. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25:19-37.
5. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderate severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-1811.
6. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117:49-57.
7. Faubion WA Jr, Loftus EV, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255-260.
8. Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003;125:1576-1582.
9. Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of disease. Gut 2001; 49:777-782.
10. Hawthorne AB, Travis SPL, the BSG Clinical Trials Network. Outcome of inpatient management of severe ulcerative colitis: a BSG Clinical Network Survey [abstract]. Gut 2002; 50:A16.
11. Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992; 103:1444-1451.
12. Wolters FL, Russel MG, Stockbrugger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20:483-496.
13. Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001;120:1093-1099.
14. Reddy SI, Friedman S, Telford JJ, et al. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol 2005; 100:1357-1361.
15. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameter Committee. Am J Gastroenterol 2004; 99:1371-1385.
16. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2005; (1):CD003715.
17. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003; (4):CD00031.
18. Sandborn WJ, Lofberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebocontrolled trials. Am J Gastroenterol 2005; 100:1780-1787.
19. Pearson D, May GR, Fick G, et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; (2):CD000067.
20. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342:1627-1632.
21. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126:402-413.
22. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopical picture of attacks of Crohn's disease: evolution on prednisolone. Groupe d'etude therapeutique des affections inflammatoires digestives. Gastroenterology 1990; 98:811-818.
23. D'Haens G, van Deventer S, van Hogezand R, et al. Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999; 116:1029-1034.
24. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002; 359:1541-1549.
25. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
26. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
27. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
28. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (3):CD005112.
29. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333. Well designed, large dose-finding study, showing the efficacy of adalimumab in inducing remission in Crohn's disease patients with active disease.
30. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65. Study showing that adalimumab maintains remission in Crohn's disease patients responding to adalimumab induction therapy through 1 year.
31. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807-818.
32. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006; 33:2398-2408.
33. Targan SR. Current limitations of IBD treatment: where do we go from here? Ann N Y Acad Sci 2006; 1072:1-8.
34. Sandborn WJ, Colombel JR, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353:1912-1925.
35. Mannon PJ, Fuss IJ, Mayer L, et al. Antiinterleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069-2079.
36. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human antiinterleukin 6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989-996.
37. Targan S, Salzberg BA, Mayer L, et al. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients, refractory to treatment with iv steroids. Gastroenterology 2005; 128:A-75.
38. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507.
39. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350:309-318.
40. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 2000; 343:1586-1593.
41. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004; 63:149-155.
42. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early active rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3423-3443.
43. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381-3390.
44. Jaspers GJ, Verkade HJ, Escher JC, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006; 12:831-836.
45. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18:425-431.
46. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895-902.
47. Hommes DW, Baert F, van Assche G, et al. Management of recent onset Crohn's disease: a controlled randomized trialcomparing step-up and top-down therapy. Gastroenterology 2005; 128 (Suppl 2):A577.
48. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4:621-630. Since no long-term randomized studies have been published, this registry provides the best available data on the side effects of infliximab in Crohn's disease patients in the long run.
49. Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346:623-626.
50. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565-2570.
51. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265-267. Report of the occurrence of aggressive T-cell lymphomas in young Crohn's disease patients exposed to infliximab. Although rare, this kind of potentially fatal complication should be taken into account when prescribing anti-TNF compounds to young Crohn's disease patients.
52. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006; 55:228-233.
53. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121-1125.
54. Sahmoud T, Hoctin-Boes G, Modigliani R, et al. Identifying patients with high risk of relapse in quiescent Crohn's disease. The GETAID group. Gut 1995; 37:811-818.
55. Brignola C, Campieri M, Bazzocchi G, et al. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986; 8:1490-1494.
56. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55:1124-1130. In this study, parameters predicting disease recurrence were identified in a unique large European cohort of Crohn's disease patients followed for 10 years.
57. Nishio Y, Ando T, Maeda O, et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006; 55:1768-1773.